Little Green Pharma Ltd. · ASX:LGP
Little Green Pharma — Merger or Acquisition (February 2026)
19 slides from Little Green Pharma's merger presentation, Feb 3, 2026
Slide 1: Proposed Little Green Pharma and Cannatrek Merger
ASX:LGP 3 February 2026 Proposed Little Green Pharma and Cannatrek Merger The Most Trusted Medicinal Cannabis Brand
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Little Green Pharma No liability taxation situation, financial situation or needs. This document sentiment, product and operation risks, the recruitment and Ltd (ACN 615 586 215) (“LGP”) in relation to the proposed consists purely of factual informat
Slide 3: Executive summary
Executive summary Little Green Pharma Ltd (LGP) has entered into a Scheme Implementation Deed with Cannatrek Ltd (Cannatrek), under which LGP proposes to acquire 100% of Cannatrek via a scheme of arrangement. This transaction represents a market- shaping merger, delivering: Transaction overview • a
Slide 4: Why now? The cannabis market inflection
Why now? The cannabis market inflection Scale and distribution The combined entity leverages • The merger combines two of Australia’s largest and most successful medicinal cannabis significant infrastructure to companies resulting in a pro-forma FY254 revenue of $112.3m and Adj. EBITDA of $13.0m cap
Slide 5: Little Green Pharma (pre acquisition)
Little Green Pharma (pre acquisition) $36.8m $2.9m $2.4m Revenue Adj. EBITDA Cash Strong FY25 Financial 20+ TPA Performance 33 PRODUCTS 4 FACILITIES FINISHED FLOWER CAPACITY 11 13 SPONSORED 92 STAFF ACROSS 20+ STRAINS DISTRIBUTION TERRITORIES STUDIES / TRIALS 5 COUNTRIES GENETICS BANK 5 1. Numbers a
Slide 6: Overview
Overview Australian licensed manufacturer and Operates within the medicinal cannabis supply chain distributor of medicinal cannabis products, sourcing bulk or finished medicinal cannabis from with operations spanning GMP-certified licensed domestic and international producers, storage and packaging,
Slide 7: Cannatrek overview - operations
Cannatrek overview - operations A nationally integrated platform delivering GMP-certified THC and CBD products from source to pharmacy Centralised operations National distribution Leading in-market Digital infrastructure across VIC & QLD model products connectivity Shepparton: Fulfilment via direct
Slide 8: Strategic rationale
Strategic rationale
Slide 9: Strategic rationale
Strategic rationale • Immediate 3x revenue increase from $36.8m standalone base to $112.3m1 pro-forma, creating a leading fully vertically Immediate revenue integrated medicinal cannabis group with operations spanning cultivation, GMP-certified manufacturing and packaging, scaling distribution and c
Slide 10: Combined FY2025 Financials
Combined FY2025 Financials FY20251 (A$) LGP Cannatrek Pro forma Synergy opportunities are Revenue2 $36.8m $75.5m $112.3m expected to come from such areas as leveraging Cannatrek’s latent Australian GMP-certified Adjusted EBITDA3 $2.9m $10.1m $13.0m manufacturing for the Australian market and LGP Ope
Slide 11: Key transaction terms
Key transaction terms
Slide 12: Key Terms of the Proposed Acquisition
Key Terms of the Proposed Acquisition • LGP and Cannatrek have entered into a binding Scheme Implementation Deed under which Cannatrek agrees to propose a scheme of arrangement between Cannatrek and its Overview shareholders under Part 5.1 of the Corporations Act 2001 (Cth). • Under the terms of the
Slide 13: Indicative timetable
Indicative timetable First Court Hearing (convening order) 6 March 2026 Scheme Booklet dispatched to shareholders 10 March 2026 Scheme and LGP General Meetings (shareholder votes) 10 April 2026 Second court hearing (approval of scheme) 21 April 2026 Scheme becomes effective 22 April 2026 Implementat
Slide 14: The case in three points
The case in three points • Successfully "executes" the roll-up of two market leaders to create a vertically integrated 1 Strategy powerhouse with $112.3m1 in revenue – effectively 3x LGP's standalone revenue scale validation • Helps achieves the critical mass required to navigate a maturing market a
Slide 15: Revenue by segment
Revenue by segment ($000’s) Revenue by 12,000 segment 10,000 8,000 6,000 Record revenue of $10.7 million 4,000 (unaudited), up over 5% on prior 2,000 quarter and up over 10% on prior corresponding period - FY25Q3 FY25Q4 FY26Q1 FY26Q2 FY26Q3 European sales up 30% on the prior Australia Europe quarter
Slide 16: European market update
European market Germany update A record 56.9 tonnes1 of cannabis was imported into Germany in CY25Q3, up 19% quarter on prior quarter for a total 142.3 tonnes for first three reported quarters of 2025, with Denmark remaining a top 3 exporter German government continues to finalise proposed additiona
Slide 17: European market update (cont.)
European market update (cont.) Spain In January 2026, the Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS) published the registration procedure for standardised cannabis preparations and confirming the Spanish regulatory framework is largely proceeding according to schedule LGP with m
Slide 18: US cannabis market
US cannabis market In December 2025, President Trump signed an Executive Order requiring the rescheduling of cannabis from Schedule I to Schedule III The Executive Order is Early growth phase Shake-out phase Growth phase Market maturity regarded as the most meaningful federal cannabis reform in more
Slide 19: Q&A
Q&A Paul Long, Managing Director A world of difference investor.littlegreenpharma.com
Little Green Pharma — Merger or Acquisition (February 2026) on 6ix